{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018147","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.888262+00:00","generated_at":"2026-06-23T14:24:12.625076+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Beam Therapeutics enters license collaboration with Orbital; will consolidate it financially","bullets":["Beam receives 75M shares of Orbital common stock; expects to consolidate Orbital under ASC 810.","Cross-licenses for non-viral delivery and RNA design; exclusive fields for each party run three years.","Beam's Giuseppe Ciaramella becomes Orbital interim CEO; other Beam executives take interim leadership roles.","Three Beam directors (Burow, Evans, Maraganore) join Orbital board; ARCH Venture Partners holds Orbital stock."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018147","json":"https://secwatch.observer/filing/0000950170-22-018147.json","markdown":"https://secwatch.observer/filing/0000950170-22-018147.md","text":"https://secwatch.observer/filing/0000950170-22-018147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022018147/0000950170-22-018147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022018147/beam-20220902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:24:12.625076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}